

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Poulvac IBMM + ARK lyophilisate for oculonasal suspension for chickens

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dose contains:

#### **Active Substances:**

Live avian infectious bronchitis virus  
(strain Massachusetts1263 and strain Arkansas 3168)

$10^{3.3} - 10^{5.8}$  EID<sub>50</sub>\*

\*EID<sub>50</sub>: Embryo infective dose 50%.

#### **Excipients:**

<b>Qualitative composition of excipients and other constituents</b>
Mannitol
Inositol
Gelatin
N Z Case Plus

Off-white to cream coloured lyophilisate.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Chickens (broilers).

#### **3.2 Indications for use for each target species**

For the active immunisation of broilers to reduce the severity of upper respiratory tract infections caused by Massachusetts and 793/B/91-type strains of avian infectious bronchitis virus.

Onset of immunity: 21 days after vaccination.

Duration of immunity: 6 weeks after vaccination.

Protection has also been demonstrated in the presence of maternally derived antibodies.

### 3.3 Contraindications

None.

### 3.4 Special warnings

Vaccinate healthy animals only.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

The vaccine should not be used if an intercurrent infection is suspected.  
The vaccine should not be used at sites where both broilers and breeders are kept.  
Chickens should not be re-vaccinated.  
The vaccine should only be used after it has been established that 793/B/91 like avian infectious bronchitis virus serotypes are epidemiologically relevant.  
The vaccine strains can spread to in contact birds for up to 30 days after vaccination.  
Special precautions should be taken to avoid spreading of the vaccine strain to pheasants.

It is recommended to vaccinate all chickens on a site with this product.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Personal protective equipment consisting of goggles and dust mask or a helmet with filtered air circulation should be worn when handling the veterinary medicinal product.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Chickens (broilers):

Common (1 to 10 animals / 100 animals treated):	Respiratory signs (including gasping, snicking and raling) <sup>1</sup>
---	--

<sup>1</sup>Generally mild; may be observed for approximately three days.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder <or its local representative> or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Do not use in birds intended for laying or breeding.

### **3.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### **3.9 Administration routes and dosage**

One dose of vaccine per bird by spray administration (oculonasal use) from one day of age.

This vaccine has been used in most types of spray equipment handsprayers (e.g. ASL Polyspray 2), knapsack sprayers (e.g. Birchmeyer with 0.55 or 1.6 mm spray nozzle, Gloria with 1.0 mm nozzle) or automatic spraying equipment (e.g. Bimex). The apparatus should be set to deliver a coarse spray (droplet size of 80-160 micrometres), allowing a dose of 0.5 ml per bird.

The lyophilised vaccine should be reconstituted with water of good quality at room temperature e.g. deionised water or good quality drinking water.

The lyophilised vaccine should be reconstituted as follows:

Remove the aluminium cap from the vial. To reconstitute the lyophilised vaccine, the rubber stopper should be removed whilst the vial is immersed in a plastic measuring jug containing 0.5 litre of clean cool water.

Half fill the vial with water, replace the stopper and shake to remove any remnants in the vial.

The content of the vial should then be added to the water in the jug, mixed well and transferred to the sprayer tank and thoroughly mixed. For the 5,000 dose vial a total amount of 2.5 l water is required and for the 10,000 dose vial a total amount of 5 l water should be used.

The chickens should be sprayed in chick boxes or brooding rings in the house to avoid loss of vaccine virus.

Upon reconstitution, transparent to white opaque suspension (depending on the volume of water used).

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Administration of a 10-fold overdose does not result in symptoms different from those mentioned in section 3.6.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI01AD07**

This vaccine is intended to stimulate active immunity against avian infectious bronchitis virus, strains Massachusetts type and 793/B/91 like (Arkansas).

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after reconstitution according to directions: 2 hours.

### **5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

### **5.4 Nature and composition of immediate packaging**

Hydrolytic type I glass vials closed with butyl rubber stopper and sealed with an aluminium crimp cap.

#### Pack sizes:

Box of 10 x 5,000 doses.  
Box of 10 x 10,000 doses.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater <or household waste>.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium S.A.  
2nd Floor, Building 10  
Cherrywood Business Park  
Loughlinstown  
Dublin 18  
D18 T3Y1  
Ireland

**7. MARKETING AUTHORISATION NUMBER**

Vm 60021/3094

**8. DATE OF FIRST AUTHORISATION**

25 January 2001

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

June 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

*Gavin Hall*

Approved: 26 June 2025